Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07256197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis

Study acronym: PICASO
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jan 1, 2026 to Apr 1, 2026
    • Eligibility criteria expanded, about 10 words
    • Collaborators: 5 to 6
    v3
  2. Start date: Dec 1, 2025 to Jan 1, 2026v2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 165 words
    • Secondary endpoints: 5 to 4
    • Study description shortened, about 18 words
    • Study title shortened, about 4 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Calcific aortic stenosis (CAS) can cause severe adverse cardiac events, but there are currently no effective drugs that can prevent or delay the progression of the disease. Our trial aims to investigate the effect of PCSK9 inhibitors on preventing or delaying the progression of CAS.
Trial Details
NCT Number NCT07256197
Lead Sponsor Beijing Anzhen Hospital
Collaborators: Beijing Jishuitan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing Hospital, Nanchong Central Hospital, Peking University First Hospital, Beijing Luhe Hospital
Conditions
(from sponsor)		 Aortic Stenosis, Calcific
Related terms Aortic Valve, Calcification of
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov